It notes enhancements with new drug categories such as cholinesterase inhibitors.
The size of the therapeutics market is forecasted to increase by $5.41 billion from 2024-2028, at an estimated compound annual growth rate of 10.03% during this time period, according to Technavio.
According to its analysis, Technavio stated that market growth is being driven by availability, research, and development of novel biomarkers, along with a trend towards the emergence of regenerative therapies. However, a challenge exists due to the high cost of developing therapeutics.
As Alzheimer’s disease continues to be a significant public health issue, its therapeutic market is witnessing advancements in treatment options, including the introduction of drug classes such as cholinesterase inhibitors and Amyloid beta inhibitors. Biological therapies, such as Tau antibody treatments, are also in development.
Technavio reported that high rates of prescription are driven by factors of worsening life expectancy and worsening memory impairment.
Distributors, consisting of healthcare facilities, pharmacies, and e-commerce platforms, strive to enhance accessibility. At the same time, mobile phones and the Internet enable access to necessary medications through online retailers.
Despite these advancements, there are still no disease-modifying treatments for the disease. Researchers continue to work on developing curative therapies, focusing on understanding the underlying mechanisms of neuronal damage and cognitive impairment, as noted by Technavio.
